Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation for Type 1 Diabetes With Diabetic Ketoacidosis
Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation for Type 1 Diabetes With Diabetic Ketoacidosis
This is a phase II trial in individuals who have been diagnosed with type 1 diabetes within
 the previous 12 months and suffered from diabetic ketoacidosis at onset of disease. The
 purpose of this study is to determine whether allogeneic umbilical cord mesenchymal stem cell
 transplantation is effective in the treatment of patients with severe type 1 diabetes.
To assess the clinical efficacy of allogeneic umbilical cord mesenchymal stem cell
 transplantation in the treatment of patients with severe type 1 diabetes, defined as with the
 history of diabetic ketoacidosis from diagnosis. All the patients are intravenously
 administrated with single-dose or double-dose umbilical cord mesenchymal stem cell and
 followed up for 36 months. Clinical and laboratory manifestations are compared before and
 after transplantation.
Inclusion Criteria:

 -  Type 1 diabetes

 -  Duration of disease less than 12 months from diagnosis

 -  With the history of diabetic ketoacidosis

 Exclusion Criteria:

 -  Pregnancy

 -  Severe psychiatric disorder

 -  Severe organic impairment(renal,hepatic,cardiac,pulmonary)

 -  Active infectious disease

 -  Previous or present neoplastic disease